spacer
home > epc > summer 2018 > a blemish on good science
PUBLICATIONS
European Pharmaceutical Contractor

A Blemish on Good Science

In scientific research, objective data collection is critical to making conclusions that are free from bias. The importance of minimising subjectivity is particularly important in dermatology clinical trials where clinically acceptable methods of assessing disease symptoms or treatment response are largely based on a physician’s subjective assessment.

Dermatologists assess skin lesions and treatment responses using different observer-rated scales, such as the Eczema Area and Severity Index (EASI) and the Psoriasis Area and Severity Index (PASI). Both rely on visual assessments of symptoms, such as erythema (redness). This traditional approach of ‘eye-balling lesions’ results in subjective measurements prone to inter- and intra-observer variability (1). They can even vary at different times of the day.

Developing processes to objectively measure outcomes in dermatology clinical trials should be a priority for sponsors and investigators in this field. Thought leaders, including Dr James Milbauer, believe that, in the not-too-distant future, imaging technology and software will enable clinicians to scan, measure, and objectively assess patients and clinical trial participants (2). Until this technology becomes a reality, the pharmaceutical industry will continue to rely on alternative established strategies to mitigate the current lack of objectivity in measuring outcomes for dermatology trials. This article will discuss these strategies and the research that has created the first steps towards objective measurements for dermatology trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Elisabeth Rowold, Director of Project Management in the dermatology division (Europe), has more than 23 years of experience in the pharma industry and more than 14 years of experience in the conduct and oversight of clinical trials spanning all phases of cutaneous safety and efficacy studies. Elisabeth oversees the Novella Project Management activities in Europe and is responsible for providing strategic leadership, organisation, training, and ongoing evaluation and support to the Clinical Operations group.
spacer
Dr Elisabeth Rowold
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement